본문 바로가기
KERD
논문KCI 등재

Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions

Vinay Sundaram|Sammy Saab|Duminda Suraweera
거트앤리버 소화기연관학회협의회|2016.07|Gut and Liver|제10권 제4호|pp. 509-519

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Liver cirrhosisLiver diseasesHepatic encephalopathyMinimal hepatic encephalopathy

초록

Hepatic encephalopathy is a spectrum of neurocognitive manifestations often seen in patients with liver injury or rarely in patients with portosystemic shunting without liver injury. It can be divided into minimal (covert) hepatic encephalopathy and overt hepatic encephalopathy, depending on the severity. Patients with hepatic encephalopathy have compromised clinical outcomes, decreased quality of life, and increased healthcare utilization, often resulting in a heavy financial and personal burden on caregivers. The diagnosis remains largely clinical, with the exclusion of possible other causes for the altered mental status. Current treatment strategies include nonabsorbable disaccharides and antibiotics. This review will focus on the diagnosis, management and clinical impact of hepatic encephalopathy.

Abstract

Hepatic encephalopathy is a spectrum of neurocognitive manifestations often seen in patients with liver injury or rarely in patients with portosystemic shunting without liver injury. It can be divided into minimal (covert) hepatic encephalopathy and overt hepatic encephalopathy, depending on the severity. Patients with hepatic encephalopathy have compromised clinical outcomes, decreased quality of life, and increased healthcare utilization, often resulting in a heavy financial and personal burden on caregivers. The diagnosis remains largely clinical, with the exclusion of possible other causes for the altered mental status. Current treatment strategies include nonabsorbable disaccharides and antibiotics. This review will focus on the diagnosis, management and clinical impact of hepatic encephalopathy.

참고문헌 (100)

  1. Stepanova M, "In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009", Clin Gastroenterol Hepatol, 10(e1), pp.1034~1041 (2012)
  2. Parekh PJ, "Ammonia and its role in the pathogenesis of hepatic encephalopathy", Clin Liver Dis, 19, pp.529~537 (2015)
  3. Poh Z, "A current review of the diagnostic and treatment strategies of hepatic encephalopathy", Int J Hepatol, 2012, pp.480309~ (2012)
  4. Brusilow SW, "Hyperammonemic encephalopathy", Medicine, 81, pp.240~249 (2002)
  5. Häussinger D, "Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?", J Hepatol, 32, pp.1035~1038 (2000)
  6. Zhang XD, "Multimodality magnetic resonance imaging in hepatic encephalopathy: an update", World J Gastroenterol, 20, pp.11262~11272 (2014)
  7. Häussinger D, "Pathogenetic mechanisms of hepatic encephalopathy", Gut, 57, pp.1156~1165 (2008)
  8. Reinehr R, "Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices", Glia, 55, pp.758~771 (2007)
  9. Albrecht J, "Glutamine: a Trojan horse in ammonia neurotoxicity", Hepatology, 44, pp.788~794 (2006)
  10. Görg B, "Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy", Hepatology, 52, pp.256~265 (2010)
  11. Ahboucha S, "Reduced brain levels of DHEAS in hepatic coma patients: significance for increased GABAergic tone in hepatic encephalopathy", Neurochem Int, 61, pp.48~53 (2012)
  12. Sergeeva OA, "GABAergic transmission in hepatic encephalopathy", Arch Biochem Biophys, 536, pp.122~130 (2013)
  13. Jones EA, "Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy", Metab Brain Dis, 17, pp.275~281 (2002)
  14. Kerlan RK Jr, "Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts", J Vasc Interv Radiol, 6, pp.917~921 (1995)
  15. McCrea M, "Neuropsychological characterization and detection of subclinical hepatic encephalopathy", Arch Neurol, 53, pp.758~763 (1996)
  16. Weissenborn K, "Neurological and neuropsychiatric syndromes associated with liver disease", AIDS, 19(3), pp.S93~S98 (2005)
  17. Montagnese S, "Sleep-wake abnormalities in patients with cirrhosis", Hepatology, 59, pp.705~712 (2014)
  18. Bajaj JS, "Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy", Hepatology, 50, pp.2014~2021 (2009)
  19. Bajaj JS, "Persistence of cognitive impairment after resolution of overt hepatic encephalopathy", Gastroenterology, 138, pp.2332~2340 (2010)
  20. Umapathy S, "Persistence of cognitive impairment after resolution of overt hepatic encephalopathy", Am J Gastroenterol, 109, pp.1011~1019 (2014)
  21. Bajaj JS, "Review article: the modern management of hepatic encephalopathy", Aliment Pharmacol Ther, 31, pp.537~547 (2010)
  22. Mardini H, "Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant", Gastroenterology, 135, pp.1582~1590 (2008)
  23. Bajaj JS, "Validation of encephalapp, smartphone-based stroop test, for the diagnosis of covert hepatic encephalopathy", Clin Gastroenterol Hepatol, 13(e1), pp.1828~1835 (2015)
  24. Sharma P, "Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis", Hepatobiliary Pancreat Dis Int, 9, pp.27~32 (2010)
  25. Montagnese S, "Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach", Metab Brain Dis, 19, pp.281~312 (2004)
  26. Bajaj JS, "Review article. The design of clinical trials in hepatic encephalopathy: an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN)consensus statement", Aliment Pharmacol Ther, 33, pp.739~747 (2011)
  27. Conn HO, "Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial", Gastroenterology, 72(4 Pt 1), pp.573~583 (1977)
  28. Ge PS, "Serum ammonia level for the evaluation of hepatic encephalopathy", JAMA, 312, pp.643~644 (2014)
  29. Bustamante J, "Prognostic significance of hepatic encephalopathy in patients with cirrhosis", J Hepatol, 30, pp.890~895 (1999)
  30. Christensen E, "Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis: survival and prognostic factors", Scand J Gastroenterol, 24, pp.999~1006 (1989)
  31. Saunders JB, "A 20-year prospective study of cirrhosis", Br Med J, 282, pp.263~266 (1981)
  32. Fichet J, "Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy", J Crit Care, 24, pp.364~370 (2009)
  33. Wong RJ, "Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation", Liver Transpl, 20, pp.1454~1461 (2014)
  34. Patidar KR, "Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization", Am J Gastroenterol, 109, pp.1757~1763 (2014)
  35. Neff GW, "Update on the management of cirrhosis: focus on cost-effective preventative strategies", Clinicoecon Outcomes Res, 5, pp.143~152 (2013)
  36. Saab S, "Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy", Int J Gen Med, 8, pp.165~173 (2015)
  37. Volk ML, "Hospital readmissions among patients with decompensated cirrhosis", Am J Gastroenterol, 107, pp.247~252 (2012)
  38. Riggio O, "Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy", Clin Gastroenterol Hepatol, 9, pp.181~183 (2011)
  39. Bajaj JS, "Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test", Hepatology, 50, pp.1175~1183 (2009)
  40. Kircheis G, "Hepatic encephalopathy and fitness to drive", Gastroenterology, 137(e9), pp.1706~1715 (2009)
  41. Román E, "Minimal hepatic encephalopathy is associated with falls", Am J Gastroenterol, 106, pp.476~482 (2011)
  42. Bajaj JS, "The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers", Am J Gastroenterol, 106, pp.1646~1653 (2011)
  43. Strauss E, "Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy", Hepatogastroenterology, 39, pp.542~545 (1992)
  44. Amodio P, "The nutritional management of hepatic encephalopathy in patients with cirrhosis:International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus", Hepatology, 58, pp.325~336 (2013)
  45. Chadalavada R, "Nutrition in hepatic encephalopathy", Nutr Clin Pract, 25, pp.257~264 (2010)
  46. Bémeur C, "Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure", J Nutr Metab, 2010, pp.489823~ (2010)
  47. Holecek M, "Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications", Nutrition, 29, pp.1186~1191 (2013)
  48. Holecek M, "Ammonia and amino acid profiles in liver cirrhosis:effects of variables leading to hepatic encephalopathy", Nutrition, 31, pp.14~20 (2015)
  49. Tsien CD, "Late evening snack: exploiting a period of anabolic opportunity in cirrhosis", J Gastroenterol Hepatol, 27, pp.430~441 (2012)
  50. Gluud LL, "Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials", J Nutr, 143, pp.1263~1268 (2013)
  51. Vilstrup H, "Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver", Hepatology, 60, pp.715~735 (2014)
  52. Als-Nielsen B, "Nonabsorbable disaccharides for hepatic encephalopathy", Cochrane Database Syst Rev, 2, pp.CD003044~ (2004)
  53. Sharma P, "Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy", Eur J Gastroenterol Hepatol, 22, pp.526~531 (2010)
  54. Bajaj JS, "Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients", Aliment Pharmacol Ther, 31, pp.1012~1017 (2010)
  55. Sharma P, "Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose", J Gastroenterol Hepatol, 27, pp.1329~1335 (2012)
  56. Bajaj JS, "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis", Hepatology, 55, pp.1164~1171 (2012)
  57. Bass NM, "Rifaximin treatment in hepatic encephalopathy", N Engl J Med, 362, pp.1071~1081 (2010)
  58. Mullen KD, "Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy", Clin Gastroenterol Hepatol, 12(e2), pp.1390~1397 (2014)
  59. Neff GW, "Durability of rifaximin response in hepatic encephalopathy", J Clin Gastroenterol, 46, pp.168~171 (2012)
  60. Mohammad RA, "Combination therapy for the treatment and prevention of hepatic encephalopathy", Ann Pharmacother, 46, pp.1559~1563 (2012)
  61. Leise MD, "Management of hepatic encephalopathy in the hospital", Mayo Clin Proc, 89, pp.241~253 (2014)
  62. Pedretti G, "Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial", Ital J Gastroenterol, 23, pp.175~178 (1991)
  63. Jiang Q, "Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis", Eur J Gastroenterol Hepatol, 20, pp.1064~1070 (2008)
  64. Sharma BC, "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", Am J Gastroenterol, 108, pp.1458~1463 (2013)
  65. Hawkins RA, "Neomycin reduces the intestinal production of ammonia from glutamine", Adv Exp Med Biol, 368, pp.125~134 (1994)
  66. Morgan MH, "Treatment of hepatic encephalopathy with metronidazole", Gut, 23, pp.1~7 (1982)
  67. Shavakhi A, "Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy", J Res Med Sci, 19, pp.703~708 (2014)
  68. Dhiman RK, "Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis:a randomized, controlled trial", Gastroenterology, 147(e3), pp.1327~1337 (2014)
  69. Lunia MK, "Probiotics prevent hepatic encephalopathy in patients with cirrhosis:a randomized controlled trial", Clin Gastroenterol Hepatol, 12(e1), pp.1003~1008 (2014)
  70. Agrawal A, "Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy", Am J Gastroenterol, 107, pp.1043~1050 (2012)
  71. Zhao LN, "Probiotics can improve the clinical outcomes of hepatic encephalopathy: an update meta-analysis", Clin Res Hepatol Gastroenterol, 39, pp.674~682 (2015)
  72. Manning RT, "Management of hepatocerebral intoxication", N Engl J Med, 258, pp.55~62 (1958)
  73. Rahimi RS, "Lactulose vs polyethylene glycol 3350: electrolyte solution for treatment of overt hepatic encephalopathy. The HELP randomized clinical trial", JAMA Intern Med, 174, pp.1727~1733 (2014)
  74. Laccetti M, "Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study", Dig Liver Dis, 32, pp.335~338 (2000)
  75. Rockey DC, "Randomized, doubleblind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy", Hepatology, 59, pp.1073~1083 (2014)
  76. Ventura-Cots M, "Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study", J Clin Gastroenterol, 47, pp.881~887 (2013)
  77. Jover-Cobos M, "Treatment of hyperammonemia in liver failure", Curr Opin Clin Nutr Metab Care, 17, pp.105~110 (2014)
  78. Bai M, "l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a metaanalysis of randomized controlled trials", J Gastroenterol Hepatol, 28, pp.783~792 (2013)
  79. Sundaram V, "Hepatic encephalopathy: pathophysiology and emerging therapies", Med Clin North Am, 93, pp.819~836 (2009)
  80. Chavez-Tapia NC, "A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy", Nutr J, 12, pp.74~ (2013)
  81. Mukund A, "Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience", J Vasc Interv Radiol, 23, pp.1200~1206 (2012)
  82. An J, "Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy", Aliment Pharmacol Ther, 39, pp.1418~1426 (2014)
  83. Laleman W, "Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy", Hepatology, 57, pp.2448~2457 (2013)
  84. Zuckerman DA, "Encephalopathy after transjugular intrahepatic portosystemic shunting:analysis of incidence and potential risk factors", AJR Am J Roentgenol, 169, pp.1727~1731 (1997)
  85. Forauer AR, "Transjugular intrahepatic portosystemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy: a simple design utilizing a Palmaz stent and Wallstent", J Vasc Interv Radiol, 9, pp.443~446 (1998)
  86. Sanyal AJ, "Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study", Hepatology, 20(1 Pt 1), pp.46~55 (1994)
  87. Riggio O, "Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: incidence and risk factors", Dig Dis Sci, 41, pp.578~584 (1996)
  88. Bureau C, "Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study", Gastroenterology, 126, pp.469~475 (2004)
  89. Yang Z, "Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis", J Gastroenterol Hepatol, 25, pp.1718~1725 (2010)
  90. Riggio O, "Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt", Clin Liver Dis, 16, pp.133~146 (2012)
  91. Riggio O, "Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines?", Dig Liver Dis, 42, pp.462~467 (2010)
  92. Bai M, "Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review", J Gastroenterol Hepatol, 26, pp.943~951 (2011)
  93. Guevara M, "Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration", Liver Int, 30, pp.1137~1142 (2010)
  94. Riggio O, "Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study", J Hepatol, 42, pp.674~679 (2005)
  95. Fanelli F, "Management of refractory hepatic encephalopathy after insertion of TIPS: longterm results of shunt reduction with hourglass-shaped balloonexpandable stent-graft", AJR Am J Roentgenol, 193, pp.1696~1702 (2009)
  96. Catalina MV, "Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure", Liver Int, 23(3), pp.39~43 (2003)
  97. Sen S, "Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis", J Hepatol, 43, pp.142~148 (2005)
  98. Laleman W, "Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure", Crit Care, 10, pp.R108~ (2006)
  99. Bañares R, "Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial", Hepatology, 57, pp.1153~1162 (2013)
  100. Amodio P, "Cirrhosis: a practical guide to management", pp.105~123 (2015), John Wiley & Sons

관련 논문AI추천

간성뇌증김창욱대한내과학회 · 대한내과학회지2008 · 제75권 제1호Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, doubleblind, placebo-controlled study안상봉, 이태희, 전대원, 정승원, Do Seon Song, Eileen L. Yoon, Hee Yeon Kim, Hyoung Su Kim, Jae Yoon Jeong, Myeong Jun Song, Sang Gyune Kim, Sung Eun Kim, Yong Kyun Cho, Young Kul Jung대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study김명환, 문병수, 문영명, 박효진, 백용한, 송건훈, 안상훈, 이관식, 이동기, 이상인, 이세준, 전재윤, 한광협연세대학교의과대학 · Yonsei Medical Journal2005 · 제46권 제3호Hepatic encephalopathy on magnetic resonance imaging and its uncertain differential diagnoses: a narrative review이희중, Chun Geun Lim, Myong Hun Hahm영남대학교 의과대학 · Journal of Yeungnam Medical Science2023 · 제40권 제2호Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies UpdateFukui Hiroshi거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제5호The Pallidal Index in Patients with Acute-on-Chronic Liver Disease: Is It a Predictor of Severe Hepatic Encephalopathy?이동현, 이희중, 함명훈대한자기공명의과학회 · Investigative Magnetic Resonance Imaging2017 · 제21권 제3호

이 간행물의 다른 논문 (28건)

The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease PatientsKyeong Ok Kimpp. 487-488Is Elderly Age a Simple Predictive Factor for Inadequate Bowel Preparation before Colonoscopy?Hyun Gun Kimpp. 489-490Serum Procalcitonin Is a Candidate Biomarker to Differentiate Bacteremia from Disease Flares in Patients with Inflammatory Bowel DisSeong-Eun Kimpp. 491-492Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection김유선, Jung Hwa Minpp. 493-494Towards Steroid-Free Immunosuppression after Liver TransplantationShawn J. Pelletier, Victor M. Zaydfudimpp. 495-496
원문 보기